Skip to main content
HYUNDAI BIOSCIENCE CO., LTD. logo

HYUNDAI BIOSCIENCE CO., LTD. — Investor Relations & Filings

Ticker · 048410 ISIN · KR7048410005 KO Professional, scientific and technical activities
Open in API
Filings indexed 288 across all filing types
Latest filing 2024-10-11 Major Shareholding Noti…
Country KR South Korea
Listing KO 048410

About HYUNDAI BIOSCIENCE CO., LTD.

http://www.hyundaibioscience.com/eindex…

HYUNDAI BIOSCIENCE CO., LTD. is a biotechnology company focused on developing innovative therapeutics using its proprietary drug delivery system (DDS) technology. The company's core science is based on organic-inorganic hybrid technologies designed to safely and effectively deliver active ingredients. Its main development pipeline includes CP-COV03, a broad-spectrum antiviral agent that enhances cellular autophagy to combat viral infections, and Polytaxel, an anticancer drug candidate developed with polymer transfer technologies to reduce toxicity. The company's primary focus is on creating novel treatments for viral diseases and cancer.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details the shareholding status, changes in share ownership, and specifically mentions '주식담보 연장계약 체결' (execution of stock collateral extension agreement). This type of filing is used to notify the market of significant ownership changes or collateral arrangements by major shareholders. Since it does not fit into specific categories like 'Director's Dealing' (which is for individual insider trades) or 'Major Shareholding Notification' (which is a specific category for threshold crossings), and given the regulatory nature of the form, it is classified as a Regulatory Filing (RNS).
2024-10-11 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding of Stocks, etc.), which is a standard regulatory filing in South Korea under the Capital Markets Act (Article 147). It details the shareholding status, changes in ownership, and collateral agreements (pledges) of a major shareholder (CnPharm Co., Ltd.) in Hyundai Bioscience. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema.
2024-09-27 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea (often referred to as the '5% rule' report). It details the shareholding status, changes in ownership, and purpose of holding (management influence) by a major shareholder (CnPharm Co., Ltd.) in Hyundai Bioscience. This document type is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema.
2024-09-13 Korean
투자판단관련주요경영사항(임상시험계획승인신청) (COVID19 치료제 CPCOV03의 3상 임상시험계획 신청서 제출)
Legal Proceedings Report Classification · 100% confidence The document is a regulatory filing from Hyundai Bioscience regarding the submission of a Phase 3 clinical trial application for a COVID-19 treatment. It is a standard corporate disclosure of a material event (major management matter) filed with the regulatory authority. Since it does not fit into specific categories like financial reports, dividends, or M&A, and is a formal regulatory disclosure, it is classified as a Regulatory Filing (RNS).
2024-08-27 Korean
반기보고서 (2024.06)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-annual Report) for Hyundai Bioscience Co., Ltd., covering the period from January 1, 2024, to June 30, 2024. It contains detailed financial statements, management discussion, and operational information, which aligns with the definition of an Interim/Quarterly Report (IR). H1 2024
2024-08-14 Korean
투자판단관련주요경영사항 (독점적 실시권 양도 계약 체결)
M&A Activity Classification · 100% confidence The document is a regulatory filing from Hyundai Bioscience regarding a 'Major Management Matter' (투자판단 관련 주요경영사항), specifically the signing of an exclusive licensing agreement for cancer drugs. This type of disclosure is a standard corporate announcement of a material business event, which falls under the 'Regulatory Filings' category as it does not fit into specific categories like M&A (which usually refers to corporate mergers/acquisitions of entities) or other specialized reports.
2024-06-26 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.